Study details
Enrolling now
A Study to Investigate the Safety, Tolerability, and Efficacy of BxC-I17e Single and Multiple Dose SC Injection in Patients With Moderate to Severe Atopic Dermatitis
Brexogen Inc.
NCT IDNCT06055361ClinicalTrials.gov data as of Apr 2026
Phase
Phase 1
Target enrollment
45
Study length
about 3 years
Ages
18+
Locations
3 sites in AR, PA
About this study
This trial is testing a new treatment called BxC-I17e for people with moderate to severe atopic dermatitis. The goal is to see if it's safe, well-tolerated, and helps improve the condition.
Based on ClinicalTrials.gov records.
What participants do
- 1.Take BxC-I17e (primed iMSC derived Extracellular vesicles(EV))
- 2.Take Placebo
PhasePhase 1
Primary goalIncidence of treatment-emergent adverse events (TEAEs)
Participation effort
Estimated from trial records. Details can vary by site.
Time + visits
Low8%
Logistics
Moderate50%
Logistics difficulty varies by site location and availability.
Trial highlights
Treatment details
Auto-extracted from trial records to preview treatments and outcomes.
Endpoints
Primary: Incidence of treatment-emergent adverse events (TEAEs)
Secondary: Change and percent change in Pruritus Numerical Rating Scale (NRS), Incidence, severity and relationship of adverse events(AEs), Number of abnormalities and change from baseline in Vital signs
Body systems
Dermatology